Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 16/20 | 0.60 |
| ▸ | KCNQ2 | O43526 | 16/20 | 0.60 |
| ▸ | KCNE1 | P15382 | 11/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 11/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568974 | 0.84 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL6361424 | 0.84 | KCNQ3 (0.64) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL2436172 | 0.82 | KCNQ3 (0.67) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL203109 | 0.82 | KCNQ3 (0.54) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL13076353 | 0.81 | KCNQ3 (0.51) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL16785423 | 0.81 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL5629229 | 0.81 | KCNQ3 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL9764596 | 0.80 | ALDH1A1 (0.57) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL12182424 | 0.80 | ALDH1A1 (0.57) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 | |
| SCHEMBL30317019 | 0.80 | L3MBTL1 (0.60) | KCNQ3KCNQ2KCNE1KCNQ1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-2429993-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-8841331-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-7276517-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-7169927-B2 | Indole-amide derivatives and their use as glycogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2007-01-30 | — | — | US | disclosed |
| US-7129249-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20050131016-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1485371-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003074513-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| EP-0610032-A1 | Acetanilide derivatives | ZENECA LIMITED (GB) | 1994-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | PYGL, PYGM, GYS1 | KCNQ3 3884/4885KCNQ2 4221/4885KCNE1 4098/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | KCNQ3 4311/4885KCNQ2 4109/4885KCNE1 4131/4885 |
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KCNQ3 4187/4885KCNQ2 4093/4885KCNE1 4534/4885 |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | PYGL, GYS2, GYS1 | KCNQ3 4082/4885KCNQ2 4182/4885KCNE1 2649/4885 |
| US-20050131016-A1 | Chemical compounds | PYGL, GYS1, CA9 | KCNQ3 3844/4885KCNQ2 3917/4885KCNE1 2212/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | KCNQ3 3369/4885KCNQ2 3323/4885KCNE1 3786/4885 |
| US-20160159773-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | KCNQ3 1156/4885KCNQ2 622/4885KCNE1 2544/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | KCNQ3 4187/4885KCNQ2 4093/4885KCNE1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.